Technical Analysis for BCAB - BioAtla, Inc.

Grade Last Price % Change Price Change
F 46.085 -4.45% -2.15
BCAB closed up 1.86 percent on Monday, April 12, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical BCAB trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup -4.64%
Multiple of Ten Bearish Other -4.64%
Wide Bands Range Expansion -4.64%
Oversold Stochastic Weakness -4.64%
Narrow Range Bar Range Contraction -2.87%
NR7 Range Contraction -2.87%
Wide Bands Range Expansion -2.87%
Oversold Stochastic Weakness -2.87%
Multiple of Ten Bearish Other -3.50%
Wide Bands Range Expansion -3.50%
Older End-of-Day Signals for BCAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
3x Volume Pace about 4 hours ago
2x Volume Pace about 4 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Cancers Monoclonal Antibodies Cancer Immunotherapy Health Care Small Cell Lung Cancer Melanoma Non Small Cell Lung Cancer Tumor Targeted Therapy Bladder Cancer Renal Cell Carcinoma Hepatocellular Carcinoma Cervical Cancer Nsclc Gastric Cancer Non Small Cell Lung Carcinoma

Is BCAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 76.63
52 Week Low 27.15
Average Volume 296,490
200-Day Moving Average 0.00
50-Day Moving Average 54.27
20-Day Moving Average 57.37
10-Day Moving Average 49.45
Average True Range 4.85
ADX 29.03
+DI 15.50
-DI 21.55
Chandelier Exit (Long, 3 ATRs ) 62.07
Chandelier Exit (Short, 3 ATRs ) 60.70
Upper Bollinger Band 74.23
Lower Bollinger Band 40.51
Percent B (%b) 0.23
BandWidth 58.76
MACD Line -2.45
MACD Signal Line -0.88
MACD Histogram -1.5684
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.82
Resistance 3 (R3) 55.01 53.00 53.72
Resistance 2 (R2) 53.00 51.32 52.91 53.36
Resistance 1 (R1) 50.62 50.29 51.81 50.43 52.99
Pivot Point 48.61 48.61 49.21 48.51 48.61
Support 1 (S1) 46.22 46.93 47.42 46.03 43.47
Support 2 (S2) 44.21 45.89 44.12 43.10
Support 3 (S3) 41.83 44.21 42.74
Support 4 (S4) 41.64